Torrent Pharmaceuticals Share Price
4689.50+0.00 (+1.70%)
+27.21% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
Torrent Pharmaceuticals Share Price
4689.50+0.00 (+1.70%)
+27.21% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| 8% | 12% | 13% | 21% |
| 2% | 12% | 20% | 12% |
| 22% | 27% | 30% | 27% |
| 21% | 22% | 26% | 27% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,908.7 | ₹456593 Cr | 41.64 | 8.29 | 58.23 | ₹11479 Cr |
| 11,120.5 | ₹296741 Cr | 88.24 | 42.53 | 146.01 | ₹2568 Cr |
| 4,626.2 | ₹175578 Cr | 82.66 | 14.04 | 106.21 | ₹2163 Cr |
| 2,304.4 | ₹124380 Cr | 92.83 | 8.17 | 33.94 | ₹889 Cr |
| 1,235 | ₹119700 Cr | 28.64 | 9.27 | 62.23 | ₹5040 Cr |
| 1,396.5 | ₹116771 Cr | 41.71 | 11.08 | 59.16 | ₹4196 Cr |
| 1,421.8 | ₹114397 Cr | 39.49 | 10.86 | 52.6 | ₹3879 Cr |
| 2,636.7 | ₹108641 Cr | 48.44 | 17.23 | 76.25 | ₹1913 Cr |
| 1,803.3 | ₹103971 Cr | 26.06 | 19.57 | 103.44 | ₹3505 Cr |
| 2,002.6 | ₹91413 Cr | 17.56 | 25.26 | 150.99 | ₹5333 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 | Dec 2018 | Sep 2018 | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | Sep 2016 | Jun 2016 | Mar 2016 | Dec 2015 | Sep 2015 | Jun 2015 | Mar 2015 | Dec 2014 | Sep 2014 | Jun 2014 | Mar 2014 | Dec 2013 | Sep 2013 | Jun 2013 | Mar 2013 | Dec 2012 | Sep 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹4979 Cr | ₹4921 Cr | ₹4197 Cr | ₹3303 Cr | ₹3302 Cr | ₹3178 Cr | ₹2959 Cr | ₹2809 Cr | ₹2889 Cr | ₹2859 Cr | ₹2745 Cr | ₹2732 Cr | ₹2660 Cr | ₹2591 Cr | ₹2491 Cr | ₹2491 Cr | ₹2291 Cr | ₹2347 Cr | ₹2131 Cr | ₹2108 Cr | ₹2137 Cr | ₹2134 Cr | ₹1937 Cr | ₹1995 Cr | ₹2017 Cr | ₹2056 Cr | ₹1946 Cr | ₹1966 Cr | ₹2005 Cr | ₹2022 Cr | ₹1856 Cr | ₹2051 Cr | ₹1894 Cr | ₹1872 Cr | ₹1708 Cr | ₹1463 Cr | ₹1417 Cr | ₹1362 Cr | ₹1434 Cr | ₹1443 Cr | ₹1429 Cr | ₹1551 Cr | ₹1503 Cr | ₹1542 Cr | ₹1693 Cr | ₹1947 Cr | ₹1154 Cr | ₹1168 Cr | ₹1217 Cr | ₹1114 Cr | ₹1225 Cr | ₹1015 Cr | ₹972 Cr | ₹972 Cr | ₹871 Cr | ₹797 Cr | ₹777 Cr |
| -₹10 Cr | -₹12 Cr | -₹17 Cr | -₹13 Cr | -₹27 Cr | -₹37 Cr | -₹18 Cr | ₹33 Cr | -₹16 Cr | ₹24 Cr | ₹31 Cr | -₹33 Cr | ₹26 Cr | ₹34 Cr | ₹9 Cr | -₹10 Cr | ₹16 Cr | ₹30 Cr | ₹56 Cr | ₹48 Cr | ₹51 Cr | ₹40 Cr | ₹39 Cr | ₹8 Cr | ₹6 Cr | ₹4 Cr | ₹15 Cr | ₹53 Cr | ₹34 Cr | ₹20 Cr | ₹17 Cr | ₹3 Cr | ₹10 Cr | ₹27 Cr | ₹42 Cr | ₹74 Cr | ₹78 Cr | ₹105 Cr | ₹104 Cr | ₹50 Cr | ₹43 Cr | ₹26 Cr | ₹24 Cr | ₹55 Cr | ₹71 Cr | ₹75 Cr | ₹100 Cr | ₹65 Cr | ₹72 Cr | ₹49 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹12 Cr |
| ₹4969 Cr | ₹4909 Cr | ₹4180 Cr | ₹3290 Cr | ₹3275 Cr | ₹3141 Cr | ₹2941 Cr | ₹2842 Cr | ₹2873 Cr | ₹2883 Cr | ₹2776 Cr | ₹2699 Cr | ₹2686 Cr | ₹2625 Cr | ₹2500 Cr | ₹2481 Cr | ₹2307 Cr | ₹2377 Cr | ₹2187 Cr | ₹2156 Cr | ₹2188 Cr | ₹2174 Cr | ₹1976 Cr | ₹2003 Cr | ₹2023 Cr | ₹2060 Cr | ₹1961 Cr | ₹2019 Cr | ₹2039 Cr | ₹2042 Cr | ₹1873 Cr | ₹2054 Cr | ₹1904 Cr | ₹1899 Cr | ₹1750 Cr | ₹1537 Cr | ₹1495 Cr | ₹1467 Cr | ₹1538 Cr | ₹1493 Cr | ₹1472 Cr | ₹1577 Cr | ₹1527 Cr | ₹1597 Cr | ₹1764 Cr | ₹2022 Cr | ₹1254 Cr | ₹1233 Cr | ₹1289 Cr | ₹1163 Cr | ₹1235 Cr | ₹1025 Cr | ₹982 Cr | ₹980 Cr | ₹879 Cr | ₹806 Cr | ₹789 Cr |
| ₹3922 Cr | ₹3850 Cr | ₹3349 Cr | ₹2421 Cr | ₹2423 Cr | ₹2347 Cr | ₹2196 Cr | ₹2094 Cr | ₹2148 Cr | ₹2152 Cr | ₹2065 Cr | ₹2076 Cr | ₹2036 Cr | ₹1991 Cr | ₹1960 Cr | ₹1960 Cr | ₹1775 Cr | ₹1790 Cr | ₹1732 Cr | ₹1737 Cr | ₹1645 Cr | ₹1622 Cr | ₹1520 Cr | ₹1555 Cr | ₹1547 Cr | ₹1556 Cr | ₹1566 Cr | ₹1589 Cr | ₹1627 Cr | ₹1641 Cr | ₹1543 Cr | ₹1646 Cr | ₹1573 Cr | ₹1545 Cr | ₹1495 Cr | ₹1198 Cr | ₹1172 Cr | ₹1145 Cr | ₹1236 Cr | ₹1200 Cr | ₹1168 Cr | ₹1182 Cr | ₹1079 Cr | ₹983 Cr | ₹1035 Cr | ₹1092 Cr | ₹1052 Cr | ₹982 Cr | ₹1000 Cr | ₹790 Cr | ₹898 Cr | ₹821 Cr | ₹815 Cr | ₹785 Cr | ₹673 Cr | ₹656 Cr | ₹643 Cr |
| ₹1656 Cr | ₹1652 Cr | ₹1339 Cr | ₹1075 Cr | ₹1056 Cr | ₹995 Cr | ₹946 Cr | ₹947 Cr | ₹923 Cr | ₹928 Cr | ₹914 Cr | ₹836 Cr | ₹851 Cr | ₹825 Cr | ₹736 Cr | ₹714 Cr | ₹695 Cr | ₹742 Cr | ₹617 Cr | ₹586 Cr | ₹711 Cr | ₹717 Cr | ₹621 Cr | ₹615 Cr | ₹641 Cr | ₹665 Cr | ₹563 Cr | ₹593 Cr | ₹575 Cr | ₹561 Cr | ₹490 Cr | ₹564 Cr | ₹483 Cr | ₹504 Cr | ₹406 Cr | ₹433 Cr | ₹407 Cr | ₹402 Cr | ₹399 Cr | ₹366 Cr | ₹373 Cr | ₹463 Cr | ₹511 Cr | ₹673 Cr | ₹788 Cr | ₹987 Cr | ₹262 Cr | ₹305 Cr | ₹345 Cr | ₹394 Cr | ₹360 Cr | ₹225 Cr | ₹189 Cr | ₹216 Cr | ₹228 Cr | ₹171 Cr | ₹166 Cr |
| ₹300 Cr | ₹305 Cr | ₹236 Cr | ₹45 Cr | ₹48 Cr | ₹56 Cr | ₹56 Cr | ₹57 Cr | ₹64 Cr | ₹75 Cr | ₹80 Cr | ₹80 Cr | ₹91 Cr | ₹103 Cr | ₹107 Cr | ₹102 Cr | ₹69 Cr | ₹55 Cr | ₹57 Cr | ₹62 Cr | ₹71 Cr | ₹68 Cr | ₹73 Cr | ₹91 Cr | ₹92 Cr | ₹102 Cr | ₹102 Cr | ₹111 Cr | ₹116 Cr | ₹122 Cr | ₹123 Cr | ₹133 Cr | ₹126 Cr | ₹122 Cr | ₹121 Cr | ₹80 Cr | ₹51 Cr | ₹56 Cr | ₹58 Cr | ₹48 Cr | ₹51 Cr | ₹49 Cr | ₹38 Cr | ₹43 Cr | ₹48 Cr | ₹55 Cr | ₹47 Cr | ₹50 Cr | ₹54 Cr | ₹24 Cr | ₹20 Cr | ₹16 Cr | ₹15 Cr | ₹8 Cr | ₹10 Cr | ₹7 Cr | ₹7 Cr |
| ₹737 Cr | ₹733 Cr | ₹529 Cr | ₹814 Cr | ₹791 Cr | ₹738 Cr | ₹665 Cr | ₹691 Cr | ₹661 Cr | ₹656 Cr | ₹631 Cr | ₹631 Cr | ₹559 Cr | ₹531 Cr | ₹433 Cr | ₹419 Cr | ₹463 Cr | ₹532 Cr | -₹87 Cr | ₹357 Cr | ₹472 Cr | ₹484 Cr | ₹383 Cr | ₹357 Cr | ₹384 Cr | ₹402 Cr | ₹293 Cr | ₹319 Cr | ₹296 Cr | ₹279 Cr | -₹150 Cr | ₹275 Cr | ₹205 Cr | ₹232 Cr | ₹134 Cr | ₹259 Cr | ₹272 Cr | ₹266 Cr | ₹244 Cr | ₹245 Cr | ₹253 Cr | ₹346 Cr | ₹410 Cr | ₹377 Cr | ₹681 Cr | ₹875 Cr | ₹155 Cr | ₹201 Cr | ₹235 Cr | ₹349 Cr | ₹317 Cr | ₹188 Cr | ₹152 Cr | ₹187 Cr | ₹159 Cr | ₹143 Cr | ₹139 Cr |
| ₹534 Cr | ₹566 Cr | ₹364 Cr | ₹635 Cr | ₹591 Cr | ₹548 Cr | ₹498 Cr | ₹503 Cr | ₹453 Cr | ₹457 Cr | ₹449 Cr | ₹443 Cr | ₹386 Cr | ₹378 Cr | ₹287 Cr | ₹292 Cr | ₹312 Cr | ₹354 Cr | -₹118 Cr | ₹249 Cr | ₹316 Cr | ₹330 Cr | ₹324 Cr | ₹297 Cr | ₹310 Cr | ₹321 Cr | ₹314 Cr | ₹251 Cr | ₹244 Cr | ₹216 Cr | -₹152 Cr | ₹246 Cr | ₹179 Cr | ₹163 Cr | ₹228 Cr | ₹58 Cr | ₹204 Cr | ₹188 Cr | ₹206 Cr | ₹229 Cr | ₹207 Cr | ₹292 Cr | ₹284 Cr | ₹290 Cr | ₹509 Cr | ₹650 Cr | ₹130 Cr | ₹167 Cr | ₹198 Cr | ₹256 Cr | ₹244 Cr | ₹158 Cr | ₹113 Cr | ₹149 Cr | ₹111 Cr | ₹112 Cr | ₹108 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹169 Cr | ₹169 Cr | ₹169 Cr | ₹169 Cr | ₹85 Cr | ₹85 Cr | ₹85 Cr | ₹85 Cr | ₹85 Cr | ₹85 Cr | ₹85 Cr | ₹85 Cr | ₹85 Cr | ₹42 Cr | ₹42 Cr | ₹42 Cr | ₹42 Cr | ₹42 Cr | ₹42 Cr |
| ₹8219 Cr | ₹7421 Cr | ₹6687 Cr | ₹6029 Cr | ₹5868 Cr | ₹5753 Cr | ₹4739 Cr | ₹4640 Cr | ₹4538 Cr | ₹4266 Cr | ₹3409 Cr | ₹2406 Cr | ₹1818 Cr | ₹1380 Cr | ₹1152 Cr | ₹980 Cr | ₹789 Cr | ₹609 Cr | ₹467 Cr |
| ₹8219 Cr | ₹7421 Cr | ₹6687 Cr | ₹6029 Cr | ₹5868 Cr | ₹5753 Cr | ₹4739 Cr | ₹4640 Cr | ₹4538 Cr | ₹4266 Cr | ₹3409 Cr | ₹2406 Cr | ₹1818 Cr | ₹1380 Cr | ₹1152 Cr | ₹980 Cr | ₹789 Cr | ₹609 Cr | ₹467 Cr |
| ₹8388 Cr | ₹7591 Cr | ₹6856 Cr | ₹6198 Cr | ₹5953 Cr | ₹5837 Cr | ₹4823 Cr | ₹4724 Cr | ₹4622 Cr | ₹4350 Cr | ₹3494 Cr | ₹2491 Cr | ₹1902 Cr | ₹1422 Cr | ₹1194 Cr | ₹1022 Cr | ₹831 Cr | ₹651 Cr | ₹510 Cr |
| ₹9196 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹52 L | ₹49 L | ₹46 L | ₹43 L | ₹40 L | ₹37 L | ₹4 Cr | ₹2 Cr | ₹0 | ₹0 | ₹0 |
| ₹11651 Cr | ₹1192 Cr | ₹1604 Cr | ₹2496 Cr | ₹2123 Cr | ₹2941 Cr | ₹3302 Cr | ₹3910 Cr | ₹4105 Cr | ₹2230 Cr | ₹1839 Cr | ₹2172 Cr | ₹731 Cr | ₹403 Cr | ₹224 Cr | ₹171 Cr | ₹365 Cr | ₹318 Cr | ₹337 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹2 Cr | ₹3 Cr | ₹6 Cr | ₹11 Cr | ₹11 Cr | ₹14 Cr | ₹14 Cr | ₹51 Cr | ₹98 Cr | ₹122 Cr | ₹158 Cr | ₹164 Cr | ₹23 Cr |
| ₹4972 Cr | ₹235 Cr | ₹101 Cr | -₹142 Cr | -₹300 Cr | -₹422 Cr | -₹433 Cr | -₹362 Cr | -₹276 Cr | -₹208 Cr | -₹111 Cr | ₹105 Cr | -₹18 Cr | ₹26 Cr | ₹51 Cr | ₹48 Cr | ₹50 Cr | ₹58 Cr | ₹62 Cr |
| ₹298 Cr | ₹160 Cr | ₹75 Cr | ₹75 Cr | ₹46 Cr | ₹35 Cr | ₹90 Cr | ₹22 Cr | ₹20 Cr | ₹8 Cr | ₹10 Cr | ₹8 Cr | ₹10 Cr | ₹10 Cr | ₹4 Cr | ₹44 L | ₹0 | ₹0 | ₹0 |
| ₹765 Cr | ₹501 Cr | ₹445 Cr | ₹393 Cr | ₹369 Cr | ₹370 Cr | ₹338 Cr | ₹289 Cr | ₹287 Cr | ₹263 Cr | ₹246 Cr | ₹207 Cr | ₹190 Cr | ₹130 Cr | ₹110 Cr | ₹56 Cr | ₹0 | ₹0 | ₹0 |
| ₹17686 Cr | ₹2088 Cr | ₹2224 Cr | ₹2823 Cr | ₹2238 Cr | ₹2924 Cr | ₹3299 Cr | ₹3861 Cr | ₹4142 Cr | ₹2303 Cr | ₹1995 Cr | ₹2505 Cr | ₹927 Cr | ₹620 Cr | ₹488 Cr | ₹398 Cr | ₹572 Cr | ₹541 Cr | ₹422 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹2358 Cr | ₹1820 Cr | ₹2089 Cr | ₹1679 Cr | ₹1674 Cr | ₹2067 Cr | ₹2049 Cr | ₹2097 Cr | ₹2048 Cr | ₹1749 Cr | ₹2260 Cr | ₹1828 Cr | ₹1429 Cr | ₹1068 Cr | ₹863 Cr | ₹615 Cr | ₹384 Cr | ₹313 Cr | ₹252 Cr |
| ₹2451 Cr | ₹1144 Cr | ₹1130 Cr | ₹1578 Cr | ₹1365 Cr | ₹1635 Cr | ₹1861 Cr | ₹1641 Cr | ₹1152 Cr | ₹687 Cr | ₹822 Cr | ₹446 Cr | ₹372 Cr | ₹276 Cr | ₹291 Cr | ₹313 Cr | ₹43 Cr | ₹61 Cr | ₹29 Cr |
| ₹2915 Cr | ₹1250 Cr | ₹1638 Cr | ₹1765 Cr | ₹923 Cr | ₹704 Cr | ₹1091 Cr | ₹934 Cr | ₹1626 Cr | ₹0 | ₹3 Cr | ₹319 Cr | ₹210 Cr | ₹125 Cr | ₹138 Cr | ₹100 Cr | ₹0 | ₹0 | ₹0 |
| ₹620 Cr | ₹504 Cr | ₹568 Cr | ₹425 Cr | ₹453 Cr | ₹485 Cr | ₹454 Cr | ₹493 Cr | ₹377 Cr | ₹302 Cr | ₹200 Cr | ₹231 Cr | ₹163 Cr | ₹242 Cr | ₹70 Cr | ₹87 Cr | ₹123 Cr | ₹91 Cr | ₹54 Cr |
| ₹8343 Cr | ₹4717 Cr | ₹5425 Cr | ₹5447 Cr | ₹4415 Cr | ₹4892 Cr | ₹5454 Cr | ₹5165 Cr | ₹5202 Cr | ₹2738 Cr | ₹3285 Cr | ₹2824 Cr | ₹2175 Cr | ₹1711 Cr | ₹1363 Cr | ₹1114 Cr | ₹550 Cr | ₹466 Cr | ₹334 Cr |
| ₹43614 Cr | ₹14396 Cr | ₹14506 Cr | ₹14468 Cr | ₹12606 Cr | ₹13653 Cr | ₹13577 Cr | ₹13751 Cr | ₹13967 Cr | ₹9392 Cr | ₹8775 Cr | ₹7820 Cr | ₹5004 Cr | ₹3753 Cr | ₹3048 Cr | ₹2536 Cr | ₹1953 Cr | ₹1658 Cr | ₹1266 Cr |
| ₹379 Cr | ₹156 Cr | ₹157 Cr | ₹151 Cr | ₹129 Cr | ₹123 Cr | ₹130 Cr | ₹126 Cr | ₹123 Cr | ₹109 Cr | ₹95 Cr | ₹34 Cr | ₹48 Cr | ₹93 Cr | ₹13 Cr | ₹9 Cr | ₹8 Cr | ₹11 Cr | ₹10 Cr |
| ₹14798 Cr | ₹3026 Cr | ₹3937 Cr | ₹5297 Cr | ₹4018 Cr | ₹4825 Cr | ₹5840 Cr | ₹6038 Cr | ₹6462 Cr | ₹2510 Cr | ₹2352 Cr | ₹2740 Cr | ₹1132 Cr | ₹693 Cr | ₹579 Cr | ₹572 Cr | ₹522 Cr | ₹483 Cr | ₹360 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹40405 Cr | ₹14041 Cr | ₹13485 Cr | ₹12812 Cr | ₹10728 Cr | ₹10512 Cr | ₹10334 Cr | ₹9935 Cr | ₹9449 Cr | ₹4910 Cr | ₹3794 Cr | ₹3543 Cr | ₹1420 Cr | ₹1278 Cr | ₹1200 Cr | ₹964 Cr | ₹813 Cr | ₹721 Cr | ₹646 Cr |
| ₹7227 Cr | ₹6094 Cr | ₹5346 Cr | ₹4690 Cr | ₹4306 Cr | ₹3447 Cr | ₹2801 Cr | ₹2188 Cr | ₹1595 Cr | ₹1221 Cr | ₹934 Cr | ₹710 Cr | ₹545 Cr | ₹458 Cr | ₹403 Cr | ₹329 Cr | ₹272 Cr | ₹209 Cr | ₹176 Cr |
| ₹33178 Cr | ₹7947 Cr | ₹8138 Cr | ₹8121 Cr | ₹6423 Cr | ₹7065 Cr | ₹7533 Cr | ₹7748 Cr | ₹7855 Cr | ₹3688 Cr | ₹2859 Cr | ₹2833 Cr | ₹875 Cr | ₹820 Cr | ₹797 Cr | ₹636 Cr | ₹541 Cr | ₹511 Cr | ₹470 Cr |
| ₹457 Cr | ₹367 Cr | ₹281 Cr | ₹688 Cr | ₹544 Cr | ₹744 Cr | ₹577 Cr | ₹479 Cr | ₹423 Cr | ₹463 Cr | ₹1042 Cr | ₹678 Cr | ₹534 Cr | ₹285 Cr | ₹114 Cr | ₹180 Cr | ₹110 Cr | ₹53 Cr | ₹82 Cr |
| ₹83 Cr | ₹44 Cr | ₹32 Cr | ₹43 Cr | ₹42 Cr | ₹42 Cr | ₹2 Cr | ₹2 Cr | ₹9 L | ₹9 L | ₹9 L | ₹6 L | ₹3 L | ₹3 L | ₹38 Cr | ₹20 Cr | ₹19 Cr | ₹19 Cr | ₹19 Cr |
| ₹83 Cr | ₹44 Cr | ₹32 Cr | ₹43 Cr | ₹42 Cr | ₹42 Cr | ₹2 Cr | ₹2 Cr | ₹9 L | ₹9 L | ₹9 L | ₹6 L | ₹3 L | ₹3 L | ₹38 Cr | ₹20 Cr | ₹19 Cr | ₹19 Cr | ₹19 Cr |
| ₹281 Cr | ₹294 Cr | ₹349 Cr | ₹181 Cr | ₹167 Cr | ₹97 Cr | ₹222 Cr | ₹151 Cr | ₹131 Cr | ₹182 Cr | ₹100 Cr | ₹207 Cr | ₹129 Cr | ₹63 Cr | ₹61 Cr | ₹60 Cr | ₹0 | ₹0 | ₹0 |
| ₹24 Cr | ₹10 Cr | ₹14 Cr | ₹28 Cr | ₹50 Cr | ₹37 Cr | ₹126 Cr | ₹196 Cr | ₹72 Cr | ₹122 Cr | ₹85 Cr | ₹50 Cr | ₹61 Cr | ₹24 Cr | ₹46 Cr | ₹46 Cr | ₹0 | ₹0 | ₹0 |
| ₹34221 Cr | ₹8773 Cr | ₹8894 Cr | ₹9139 Cr | ₹7312 Cr | ₹8130 Cr | ₹8596 Cr | ₹8714 Cr | ₹8705 Cr | ₹4513 Cr | ₹4086 Cr | ₹3768 Cr | ₹1600 Cr | ₹1192 Cr | ₹1061 Cr | ₹941 Cr | ₹670 Cr | ₹584 Cr | ₹571 Cr |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ₹866 Cr | ₹112 Cr | ₹141 Cr | ₹156 Cr | ₹184 Cr | ₹139 Cr | ₹2 L | ₹351 Cr | ₹492 Cr | ₹804 Cr | ₹780 Cr | ₹298 Cr | ₹186 Cr | ₹60 Cr | ₹87 Cr | ₹126 Cr | ₹122 Cr | ₹120 Cr | ₹35 Cr |
| ₹3138 Cr | ₹2541 Cr | ₹2279 Cr | ₹2230 Cr | ₹2462 Cr | ₹2681 Cr | ₹2148 Cr | ₹1935 Cr | ₹1966 Cr | ₹1559 Cr | ₹1358 Cr | ₹1067 Cr | ₹1006 Cr | ₹924 Cr | ₹532 Cr | ₹505 Cr | ₹324 Cr | ₹265 Cr | ₹231 Cr |
| ₹3031 Cr | ₹1866 Cr | ₹1844 Cr | ₹1944 Cr | ₹1632 Cr | ₹1523 Cr | ₹1649 Cr | ₹1436 Cr | ₹1253 Cr | ₹951 Cr | ₹1445 Cr | ₹1587 Cr | ₹1099 Cr | ₹688 Cr | ₹523 Cr | ₹340 Cr | ₹298 Cr | ₹267 Cr | ₹211 Cr |
| ₹1165 Cr | ₹579 Cr | ₹839 Cr | ₹571 Cr | ₹403 Cr | ₹604 Cr | ₹667 Cr | ₹816 Cr | ₹867 Cr | ₹894 Cr | ₹647 Cr | ₹567 Cr | ₹769 Cr | ₹627 Cr | ₹674 Cr | ₹479 Cr | ₹388 Cr | ₹230 Cr | ₹118 Cr |
| ₹404 Cr | ₹324 Cr | ₹328 Cr | ₹247 Cr | ₹332 Cr | ₹511 Cr | ₹441 Cr | ₹406 Cr | ₹588 Cr | ₹589 Cr | ₹368 Cr | ₹423 Cr | ₹259 Cr | ₹186 Cr | ₹116 Cr | ₹95 Cr | ₹42 Cr | ₹34 Cr | ₹23 Cr |
| ₹788 Cr | ₹200 Cr | ₹180 Cr | ₹166 Cr | ₹151 Cr | ₹63 Cr | ₹73 Cr | ₹93 Cr | ₹95 Cr | ₹83 Cr | ₹90 Cr | ₹109 Cr | ₹85 Cr | ₹76 Cr | ₹56 Cr | ₹49 Cr | ₹109 Cr | ₹158 Cr | ₹76 Cr |
| ₹9392 Cr | ₹5623 Cr | ₹5611 Cr | ₹5314 Cr | ₹5165 Cr | ₹5522 Cr | ₹4979 Cr | ₹5038 Cr | ₹5262 Cr | ₹4879 Cr | ₹4688 Cr | ₹4051 Cr | ₹3404 Cr | ₹2561 Cr | ₹1987 Cr | ₹1594 Cr | ₹1283 Cr | ₹1074 Cr | ₹695 Cr |
| ₹1049 Cr | ₹905 Cr | ₹186 Cr | -₹134 Cr | ₹750 Cr | ₹630 Cr | -₹475 Cr | -₹128 Cr | ₹60 Cr | ₹2141 Cr | ₹1403 Cr | ₹1228 Cr | ₹1230 Cr | ₹850 Cr | ₹624 Cr | ₹480 Cr | ₹733 Cr | ₹608 Cr | ₹361 Cr |
| ₹43614 Cr | ₹14396 Cr | ₹14506 Cr | ₹14468 Cr | ₹12606 Cr | ₹13653 Cr | ₹13577 Cr | ₹13751 Cr | ₹13967 Cr | ₹9392 Cr | ₹8775 Cr | ₹7820 Cr | ₹5004 Cr | ₹3753 Cr | ₹3048 Cr | ₹2536 Cr | ₹1953 Cr | ₹1658 Cr | ₹1266 Cr |
| ₹248 | ₹224 | ₹203 | ₹183 | ₹352 | ₹345 | ₹285 | ₹279 | ₹273 | ₹257 | ₹206 | ₹147 | ₹112 | ₹168 | ₹141 | ₹121 | ₹98 | ₹77 | ₹60 |
| ₹248 | ₹224 | ₹203 | ₹183 | ₹176 | ₹172 | ₹142 | ₹140 | ₹137 | ₹129 | ₹103 | ₹74 | ₹56 | ₹42 | ₹35 | ₹30 | ₹25 | ₹19 | ₹15 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹2872 Cr | ₹2673 Cr | ₹2352 Cr | ₹1847 Cr | ₹1226 Cr | ₹1526 Cr | ₹1187 Cr | ₹562 Cr | ₹931 Cr | ₹1088 Cr | ₹2343 Cr | ₹940 Cr | ₹844 Cr | ₹582 Cr | ₹359 Cr | ₹342 Cr | ₹347 Cr | ₹192 Cr | ₹149 Cr |
| ₹1301 Cr | ₹996 Cr | ₹994 Cr | ₹937 Cr | ₹1350 Cr | ₹993 Cr | ₹876 Cr | ₹1418 Cr | ₹607 Cr | ₹430 Cr | ₹552 Cr | ₹338 Cr | ₹137 Cr | ₹126 Cr | ₹80 Cr | ₹75 Cr | ₹81 Cr | ₹82 Cr | ₹60 Cr |
| -₹342 Cr | -₹481 Cr | ₹418 Cr | -₹18 Cr | -₹352 Cr | -₹338 Cr | -₹386 Cr | ₹99 Cr | -₹360 Cr | -₹125 Cr | ₹424 Cr | -₹409 Cr | -₹120 Cr | -₹422 Cr | ₹144 Cr | ₹62 Cr | -₹75 Cr | ₹10 Cr | ₹58 Cr |
| ₹3832 Cr | ₹3188 Cr | ₹3764 Cr | ₹2766 Cr | ₹2224 Cr | ₹2181 Cr | ₹1677 Cr | ₹2079 Cr | ₹1178 Cr | ₹1393 Cr | ₹3319 Cr | ₹868 Cr | ₹861 Cr | ₹286 Cr | ₹582 Cr | ₹479 Cr | ₹353 Cr | ₹284 Cr | ₹267 Cr |
| ₹3023 Cr | ₹2585 Cr | ₹3266 Cr | ₹2368 Cr | ₹1803 Cr | ₹2005 Cr | ₹1393 Cr | ₹1798 Cr | ₹894 Cr | ₹1009 Cr | ₹2742 Cr | ₹810 Cr | ₹599 Cr | ₹153 Cr | ₹499 Cr | ₹395 Cr | ₹287 Cr | ₹258 Cr | ₹242 Cr |
| -₹12712 Cr | -₹540 Cr | -₹168 Cr | -₹2415 Cr | -₹197 Cr | -₹449 Cr | ₹199 Cr | -₹241 Cr | -₹4707 Cr | -₹787 Cr | -₹838 Cr | -₹2162 Cr | -₹356 Cr | -₹242 Cr | -₹137 Cr | -₹233 Cr | -₹129 Cr | -₹40 Cr | -₹139 Cr |
| ₹10151 Cr | -₹2298 Cr | -₹2780 Cr | ₹77 Cr | -₹1781 Cr | -₹1651 Cr | -₹1549 Cr | -₹1314 Cr | ₹3417 Cr | -₹193 Cr | -₹1435 Cr | ₹1212 Cr | ₹86 Cr | ₹20 Cr | -₹193 Cr | -₹68 Cr | -₹5 Cr | -₹18 Cr | ₹31 Cr |
| ₹461 Cr | -₹253 Cr | ₹319 Cr | ₹30 Cr | -₹175 Cr | -₹95 Cr | ₹42 Cr | ₹242 Cr | -₹395 Cr | ₹29 Cr | ₹469 Cr | -₹140 Cr | ₹330 Cr | -₹68 Cr | ₹169 Cr | ₹95 Cr | ₹153 Cr | ₹200 Cr | ₹134 Cr |
| ₹573 Cr | ₹835 Cr | ₹509 Cr | ₹398 Cr | ₹573 Cr | ₹662 Cr | ₹589 Cr | ₹702 Cr | ₹1068 Cr | ₹1050 Cr | ₹612 Cr | ₹955 Cr | ₹687 Cr | ₹761 Cr | ₹605 Cr | ₹510 Cr | ₹350 Cr | ₹154 Cr | ₹21 Cr |
| ₹0 | ₹0 | ₹0 | ₹59 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹5 Cr | ₹0 | ₹8 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹83 Cr | -₹9 Cr | ₹8 Cr | ₹21 Cr | ₹53 L | ₹6 Cr | ₹31 Cr | -₹4 Cr | ₹25 Cr | -₹11 Cr | -₹40 Cr | ₹50 Cr | -₹62 Cr | -₹5 Cr | -₹13 Cr | -₹47 L | ₹7 Cr | -₹4 Cr | -₹1 Cr |
| ₹1117 Cr | ₹573 Cr | ₹835 Cr | ₹509 Cr | ₹398 Cr | ₹573 Cr | ₹662 Cr | ₹940 Cr | ₹702 Cr | ₹1068 Cr | ₹1050 Cr | ₹865 Cr | ₹955 Cr | ₹687 Cr | ₹761 Cr | ₹605 Cr | ₹510 Cr | ₹350 Cr | ₹154 Cr |
Fundamental Ratios
Consolidated
Standalone

No results found
Torrent Pharmaceuticals Share Price
4689.50+0.00 (+1.70%)
+27.21% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 3 out of 9 oscillators
RSI
50.46Neutral
STOCH %K
43.76Neutral
MACD Level(12,26)
-9.79Sell
Ultimate Oscillator
47.81Sell
Aroon Oscillator
-40.00Sell
BOP
0.90Buy
CCI
-1.13Neutral
Williams %R
-56.24Neutral
Momentum
94.50Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 6
Bearish signals: 3 out of 9 moving averages
EMA 9
4671.45Buy
SMA 9
4689.93Sell
EMA 21
4677.71Buy
SMA 21
4660.75Buy
EMA 50
4716.44Sell
SMA 50
4730.52Sell
EMA 200
4522.47Buy
SMA 200
4564.14Buy
WMA 20
4683.73Buy
Pivot
Pivot
Classic
Resistance 5
4935.43
Resistance 4
4857.73
Resistance 3
4780.03
Resistance 2
4702.33
Resistance 1
4656.67
Pivot
4624.63
Support 1
4578.97
Support 2
4546.93
Support 3
4469.23
Support 4
4391.53
Support 5
4313.83
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Torrent Pharmaceuticals Share Price
4689.50+0.00 (+1.70%)
+27.21% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 60.78% | 68.31% | 68.31% | 68.31% | 68.31% | 68.31% |
| 17.22% | 15.44% | 16.18% | 16.13% | 15.92% | 16.09% |
| 4.55% | 4.79% | 4.51% | 4.22% | 4.05% | 3.59% |
| 8.82% | 4.94% | 4.45% | 4.83% | 5.12% | 4.95% |
| 8.63% | 6.52% | 6.55% | 6.51% | 6.60% | 7.06% |
Bulk & block deals
Name
Ubs Ag
Ubs Principal Capital Asia Limited
Torrent Investments Private Limited
Torrent Investments Private Limited
Seb Asienfond Ex Japan
Seb Fund 3 Seb Pension Fund
Bnp Paribas Arbitrage
Societe Generale
Marshall Wace Investment Strategies - Eureka Fund
Marshall Wace Investment Strategiesgtops Fund
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 23 Jan 2025 | Purchase | 14.57 Cr | ₹3,252.10 | 44.81 K | Block | 0.01324 | NSE |
| 23 Jan 2025 | Sell | 14.57 Cr | ₹3,252.10 | 44.81 K | Block | 0.01324 | NSE |
| 30 Oct 2024 | Sell | 1,543.51 Cr | ₹3,104.40 | 49.72 L | Bulk | 1.307161 | BSE |
| 30 Oct 2024 | Sell | 1,542.85 Cr | ₹3,103.07 | 49.72 L | Bulk | 1.307161 | BSE |
| 07 Mar 2024 | Purchase | 17.03 Cr | ₹2,691.20 | 63.29 K | Block | 0.01664 | NSE |
| 07 Mar 2024 | Sell | 17.03 Cr | ₹2,691.20 | 63.29 K | Block | 0.01664 | NSE |
| 25 Jan 2024 | Sell | 13.93 Cr | ₹2,507.05 | 55.56 K | Block | 0.014607 | BSE |
| 25 Jan 2024 | Purchase | 118.99 Cr | ₹2,507.05 | 4.75 L | Block | 0.124782 | BSE |
| 25 Jan 2024 | Purchase | 97.35 L | ₹2,507.05 | 3.88 K | Block | 0.001021 | BSE |
| 25 Jan 2024 | Purchase | 1.09 Cr | ₹2,507.05 | 4.36 K | Block | 0.001145 | BSE |
Insider trading & SAST
Client name
Geena Malhotra
Geena Malhotra
Geena Malhotra
Geena Malhotra
Torrent Private Limited,Sudhir Uttamlal Mehta (Huf),Samir Uttamlal Mehta (Huf) ,Sudhir Uttamlal Mehta,Samir Uttamlal Mehta,Anita Sudhir Mehta,Sapna Samir Mehta,Jinal Sudhir Mehta,Jinal Sudhir Mehta,Varun Sudhir Mehta,Shaan Mehta,Amaan Mehta
Torrent Private Limited,Sudhir Uttamlal Mehta (Huf),Samir Uttamlal Mehta (Huf) ,Sudhir Uttamlal Mehta,Samir Uttamlal Mehta,Anita Sudhir Mehta,Sapna Sa
Torrent Private Limited,Sudhir Uttamlal Mehta (Huf),Samir Uttamlal Mehta (Huf) ,Sudhir Uttamlal Mehta,Samir Uttamlal Mehta,Anita Sudhir Mehta,Sapna Samir Mehta,Jinal Sudhir Mehta,Jinal Sudhir Mehta,Varun Sudhir Mehta,Shaan Mehta,Amaan Mehta
Torrent Private Limited,Sudhir Uttamlal Mehta (Huf),Samir Uttamlal Mehta (Huf) ,Sudhir Uttamlal Mehta,Samir Uttamlal Mehta,Anita Sudhir Mehta,Sapna Samir Mehta,Jinal Sudhir Mehta,Jinal Sudhir Mehta,Varun Sudhir Mehta,Shaan Mehta,Amaan Mehta
Jinesh Shah, Designated Person (In Capacity Of Trustee Of Jinesh Trust)
Torrent Investments Pvt Ltd
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 03 Jun 2026 | Designated Person | Acquisition | 0.000059 | 0 | 8.01 L | ₹4,002.99 | 200 | 01 Feb 2026 | Market Purchase | 300 | Insider Trading | — | Equity Shares |
| 03 Jun 2026 | Designated Person | Acquisition | 0.00003 | 0 | 3.94 L | ₹3,943.84 | 100 | 06 Feb 2026 | Market Purchase | 400 | Insider Trading | — | Equity Shares |
| 01 Jun 2026 | Designated Person | Acquisition | 0.00003 | 0 | 3.94 L | ₹3,943.84 | 100 | 06 Feb 2026 | Market Purchase | 400 | Insider Trading | — | Equity Shares |
| 01 Jun 2026 | Designated Person | Acquisition | 0.000059 | 0 | 8.01 L | ₹4,002.99 | 200 | 01 Feb 2026 | Market Purchase | 300 | Insider Trading | — | Equity Shares |
| 24 Dec 2024 | Promoter | Others | 26 | — | 0 | — | 4.40 Cr | 10 Apr 2020 | Release | 0 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Others | 25 | — | 0 | — | 4.23 Cr | 07 Apr 2020 | Release | 0 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Others | 26 | — | 0 | — | 4.40 Cr | 07 Apr 2020 | Release | 0 | SAST | Reg31 | — |
| 24 Dec 2024 | Promoter | Others | 26 | — | 0 | — | 4.40 Cr | 08 Apr 2020 | Release | 0 | SAST | Reg31 | — |
| 29 Nov 2024 | Trust | Acquisition | 0.274828 | 0.27 | 0 | — | 9.30 L | 27 Nov 2024 | Off Market | 9,30,144 | Insider Trading | — | Equity Shares |
| 07 Nov 2024 | Promoter | Disposal | 2.94 | 68.31 | 0 | — | 99.44 L | 30 Oct 2024 | Market | 23,11,83,400 | SAST | 29(2) | — |
Torrent Pharmaceuticals Share Price
4689.50+0.00 (+1.70%)
+27.21% past 1 Year
Torrent Pharmaceuticals is engaged in manufacturing, developing and marketing of generic pharmaceutical formulations. The company is a leading player in the areas of Cardiovascular and Central Nervous Systems, having achieved
Corporate Actions
Date
Type
Details
Company details
Torrent Pharmaceuticals Share Price
4689.50+0.00 (+1.70%)
+27.21% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Torrent Pharmaceuticals Share Price
4689.50+0.00 (+1.70%)
+27.21% past 1 Year
News
1 of 20
Block DealTORNTPHARM27 Oct 2026
Torrent Pharmaceuticals recorded a BSE block trade involving approximately 60,000 equity shares at Rs 4,630.00 per share, resulting in an aggregate transaction value of about Rs 27.78 crores. The available information does not disclose the identities of the buyer or seller, their investor classification, or any resulting change in shareholding or stake.
The transaction price was broadly in line with the company’s prevailing market price around the reported trading period. No reliable information is available on any premium or discount to the relevant market price, nor on a confirmed post-deal share price reaction attributable to the block transaction. The trade is a routine single-stock market activity and does not by itself indicate a change in Torrent Pharmaceuticals’ operating outlook.
Nomura Maintains Neutral On Torrent Pharma After Slight Q2 Miss
Stock NewsTORNTPHARM26 Oct 2026
Nomura maintained its Neutral rating on Torrent Pharmaceuticals and retained a target price of Rs 5,030. The company’s second-quarter headline performance was slightly below expectations, although the core business remained strong.
Torrent Pharmaceuticals now expects Rs 450 crores of synergies from the JB Pharmaceuticals acquisition over two years, compared with the earlier three-year timeline. The accelerated synergy realisation could support earnings and operational efficiency, while margins are expected to improve slightly in the second half of FY27 as integration and operations stabilise.
The update presents mixed operating signals, with a modest quarterly performance miss offset by resilient core operations and faster expected acquisition benefits. The development is likely to have a limited near-term impact on the stock.
Jefferies Maintains Buy Rating On Torrent Pharma With Rs 5,900 Target
Stock NewsTORNTPHARM26 Oct 2026
Jefferies has maintained its Buy rating on Torrent Pharmaceuticals with a target price of Rs 5,900. Torrent Pharma’s India base business grew 20% year on year, while Brazil delivered 21% constant-currency growth. Growth in the US business remained steady.
Integration of JB Chemicals is ahead of schedule, with half of the identified cost synergies already achieved. Revenue synergies are expected to support growth from next year. The update indicates improving integration benefits and sustained performance across key markets, with potential support for earnings growth and operating efficiencies.
Torrent Pharmaceuticals trades under the symbol TORNTPHARM on the NSE and has ISIN INE685A01028.
Citi Maintains Buy On Torrent Pharma After In Line Q2 Performance
Stock NewsTORNTPHARM26 Oct 2026
Citi has maintained its Buy rating on Torrent Pharmaceuticals and retained a target price of Rs 5,860 following an in-line second-quarter performance. Strong execution in India and Brazil offset temporary challenges related to JB integration and delayed international deliveries.
Management expects a gradual recovery in the JB business and improving India growth during the second half of the financial year. The company expects approximately Rs 450 crores in synergies from the integration, with around half expected in FY27 and the balance in FY28. The planned synergies could support future earnings growth and partially offset near-term integration-related pressure.
The development is mixed because current operating performance was in line, while recovery and synergy benefits remain forward-looking. The NSE-listed equity share has ISIN INE685A01028.
HSBC Maintains Buy Rating On Torrent Pharma With Rs 5,700 Target
Stock NewsTORNTPHARM26 Oct 2026
HSBC has maintained its Buy rating on Torrent Pharmaceuticals with a target price of Rs 5,700. Base India sales, excluding JB Pharma, increased 20% year on year. JB Pharma’s performance was affected by post-merger integration, making the recovery of its portfolio a key upcoming catalyst.
Growth in branded generics is expected to support margin expansion. The brokerage view indicates that improving domestic business momentum and a recovery in JB Pharma could strengthen earnings prospects, while integration-related weakness remains a near-term monitorable. No corporate action, regulatory order, or stock price impact was provided in the available information.
Kotak Upgrades Torrent Pharma To Buy On Strong Base Business Growth
Stock NewsTORNTPHARM26 Oct 2026
Kotak Institutional Equities upgraded Torrent Pharmaceuticals to Buy and set a target price of Rs 5,665. The company’s second-quarter performance was in line with expectations, with strong double-digit growth in the base business partly offset by slower performance at JB Pharma and in Germany, along with higher research and development costs.
JB Pharma cost synergies reached Rs 120 crores in the first half, ahead of schedule. Revenue synergies are expected to begin from the first quarter of financial year 2028. Kotak forecasts a 19% EBITDA compound annual growth rate between financial year 2026 and financial year 2029, indicating scope for earnings improvement through operating growth and acquisition synergies.
The update is mixed because the upgrade and synergy progress are positive, while slower JB Pharma and Germany growth and elevated research and development costs remain near-term offsets. Torrent Pharmaceuticals trades on the NSE under TORNTPHARM and has ISIN INE685A01028.
Torrent Pharma reports strong second quarter EBITDA growth and margin expansion
ResultTORNTPHARM23 Oct 2026
Torrent Pharmaceuticals reported second-quarter EBITDA of Rs 1,656 crores, compared with Rs 1,080 crores a year earlier and the estimate of Rs 1,625 crores. EBITDA therefore exceeded consensus by approximately 1.9 percent and increased about 53.3 percent year over year. EBITDA margin stood at 33.26 percent, broadly ahead of the 33 percent estimate. Revenue and PAT figures were not provided in the available update and are therefore not included. The EBITDA performance indicates stronger-than-expected operating profitability during the quarter.
Torrent Pharmaceuticals Q2 Profit Declines Despite Strong Revenue and EBITDA Growth
ResultTORNTPHARM23 Oct 2026
Torrent Pharmaceuticals reported consolidated Q2 FY27 revenue from operations of Rs 4,979 crores, up 50.8 percent year on year from Rs 3,302 crores. Operating EBITDA before exceptional items increased 53.8 percent year on year to Rs 1,666 crores, with the operating EBITDA margin improving to 33.5 percent from 32.8 percent. Consolidated net profit declined 9.6 percent year on year to Rs 534 crores from Rs 591 crores.
Revenue exceeded the reported consensus estimate of Rs 4,905.6 crores, while net profit was below the reported estimate of Rs 544.3 crores. Higher finance costs and depreciation and amortisation expenses weighed on profitability despite strong operating growth. The result is negative for earnings sentiment because the profit outcome missed expectations and declined year on year, although revenue growth and margin expansion provide some support.
Torrent Pharma Q2 Revenue Surges, EBITDA Improves, Net Profit Declines Year On Year
ResultTORNTPHARM23 Oct 2026
Torrent Pharmaceuticals reported Q2 revenue of Rs 4,979 crores, up 50.8% year on year from Rs 3,302 crores and above the estimated Rs 4,906 crores. Operating EBITDA increased 53.8% year on year to Rs 1,666 crores, while EBITDA margin improved to 33.5% from 32.8%. Consolidated PAT declined 9.6% year on year to Rs 534 crores from Rs 591 crores, reflecting higher expenses despite strong operating growth. The revenue increase included Rs 1,086 crores from the JB Chemicals business, while Torrent's base business revenue grew 18% to Rs 3,893 crores. India revenue rose 20% to Rs 2,181 crores. The reported revenue exceeded the available street estimate, EBITDA growth was strong, but the decline in PAT resulted in mixed earnings quality. No quarter-on-quarter figures or market reaction were provided.
Torrent Pharmaceuticals executes Rs 24.18 crores NSE block trade
Block DealTORNTPHARM16 Sept 2026
Torrent Pharmaceuticals Ltd., a leading Indian pharmaceuticals company listed on NSE and BSE, witnessed a reported block trade on the NSE amounting to approximately Rs 24.18 crores. The transaction involved about 50,233 equity shares of the company, executed at a price of Rs 4813.00 per share. The indicated deal size reflects a sizable secondary market transaction, suggestive of institutional or large investor activity, even though the specific identities of the buyer and seller have not been disclosed in the available context. As this is a secondary market block trade, it represents a transfer of ownership between market participants rather than a primary capital-raising event by the company.
At the reported block price of Rs 4813.00 per share, the trade value aligns with the aggregate consideration of around Rs 24.18 crores, based on the stated share count of roughly 50,233 shares. The block trade size is meaningful in the context of daily trading volumes, but there is no explicit information on the corresponding percentage stake change, the share of promoter or institutional holdings impacted, or any linkage to a broader strategic transaction. Details on whether the block was executed at a premium or discount to the prevailing market price at the time of trade, as well as any immediate follow-through in stock price movement post-deal, are not provided in the given context and therefore cannot be inferred with reliability. The development nevertheless highlights notable large-ticket activity in Torrent Pharmaceuticals equity on the NSE, relevant for market participants tracking ownership shifts and liquidity patterns in the stock.
Torrent Pharma sees Rs 108.35 crore BSE block trade at Rs 4,925 a share
Block DealTORNTPHARM31 Aug 2026
Torrent Pharmaceuticals Ltd, listed on NSE as TORNTPHARM and on BSE as 500420, witnessed a sizeable block trade on BSE involving shares of Torrent Pharma. The transaction size was about Rs 108.35 crores, with roughly 2.2 lakhs shares changing hands. The deal was executed at a price of Rs 4,925 per share, indicating negotiated interest between institutional or large investors rather than typical retail market flow. The identities of the buyer and seller, as well as whether the trade involved promoters, long-only funds, hedge funds, or other institutional participants, were not disclosed in the available context. As a result, the precise change in shareholding percentage, stake reallocation among key shareholders, and any potential strategic intent behind the transaction cannot be ascertained from the current information.
Given the deal value and share count, this block trade represents a notable, but not market-moving, transaction in Torrent Pharma relative to its typical cash market turnover. Block trades of this nature often reflect portfolio rebalancing, entry or exit of a mid-to-large investor, or a shift between long-term and short-term holders. However, without clarity on counterparties or whether the trade took place at a discount or premium to the prevailing market price at the time of execution, it is not possible to draw firm conclusions about directional investor sentiment or any immediate impact on the company’s valuation. No follow-through data on intraday or subsequent stock price movement post the block deal is available in the given context, so any assessment of short-term price reaction, changes in liquidity, or implications for broader sector sentiment would be speculative. The information at hand therefore supports only a factual description of the transaction’s size, execution venue, and price.
Torrent Pharma sees Rs 29.31 crores NSE block trade at Rs 4961.50
Block DealTORNTPHARM5 Aug 2026
Torrent Pharmaceuticals Ltd. witnessed a notable block trade on the NSE, signalling institutional or large-investor activity in the counter. The transaction involved approximately 59,070 shares changing hands at a negotiated price of Rs 4961.50 per share. The total deal value is reported at around Rs 29.31 crores, indicating a reasonably large secondary market transaction relative to typical on-screen liquidity for the stock. Such block deals are generally executed to facilitate sizeable share transfers in a single or few prints without causing excessive order-book disruption. The trade was reported under the block segment, which is commonly used by institutional investors, funds, or large shareholders to realign portfolios or execute strategic entry or exit moves.
The identities of the buyer and seller have not been disclosed in the available report, and there is no explicit indication whether the trade involved promoters, long-only institutions, hedge funds, or other market participants. Similarly, the exact percentage of equity represented by this block, and any resulting change in shareholding structure, is not specified and therefore cannot be inferred reliably. The agreed price of Rs 4961.50 per share provides a reference point for market participants, but in the absence of concurrent data on the prevailing market price at the time of execution, it is not possible to quantify any premium or discount embedded in the deal. The block trade, by itself, reflects concentrated interest in Torrent Pharmaceuticals Ltd. shares but does not, in isolation, convey a clear directional signal on fundamentals, earnings expectations, or corporate actions. Follow-through price action and subsequent disclosures, if any, would be required to gauge whether this transaction represents a strategic accumulation, partial exit, or routine portfolio rebalancing.
Torrent Pharmaceuticals sees Rs 53.74 crores NSE block trade at premium price
Block DealTORNTPHARM4 Aug 2026
Torrent Pharmaceuticals Ltd. witnessed a notable block trade on the NSE involving approximately 107,153 shares, with a total deal value of about Rs 53.74 crores. The transaction was executed at a price of Rs 5015.00 per share. This size of block trade indicates participation by a large investor category, such as an institution, fund, or high net-worth participant, though the identities of the buyer and seller have not been disclosed in the available context. The deal represents a meaningful secondary market transaction, but without information on the company’s total equity base, the exact percentage stake change cannot be quantified. Still, the absolute value and share count signal a sizable transfer of ownership between large market participants.
As this is a reported block trade rather than a primary issuance, the transaction does not directly alter Torrent Pharmaceuticals’ capital structure or bring fresh capital into the company. Instead, it reflects reallocation of holdings among existing or new shareholders. There is no explicit indication in the news whether the trade involved promoters, strategic investors, or long-only institutions, and therefore the strategic intent behind the transaction cannot be firmly established from the given data. The execution price of Rs 5015.00 is central to interpreting the market context; however, since the prevailing market price or intra-day range at the time of the deal is not provided, any premium or discount versus the market level cannot be objectively calculated.
The reported block trade may draw short-term attention from market participants tracking ownership flows and liquidity in Torrent Pharmaceuticals, especially in the context of large trades that can influence perceptions of institutional interest. Nonetheless, in the absence of details on buyer or seller category, stake magnitude relative to free float, and post-deal price reaction, the broader directional implications for the stock remain limited based solely on this information. Overall, the event stands as a material but routine secondary-market transaction in Torrent Pharmaceuticals on the NSE, noteworthy primarily for its size and execution price.
Torrent Pharmaceuticals reports strong Q1 EBITDA growth with margin expansion YoY
ResultTORNTPHARM30 Jul 2026
Torrent Pharmaceuticals has reported a robust operational performance for the latest reported Q1 period, with EBITDA rising to Rs 1,664 crores compared to Rs 1,032 crores in the corresponding quarter last year. This represents a strong year-on-year increase in operating profitability in absolute terms, indicating improved scale and operating leverage in the core pharmaceutical business. The reported figures underline a significant enhancement in earnings before interest, tax, depreciation and amortisation, which is a key indicator of underlying business strength, cash generation potential and the ability to fund future growth initiatives.
Alongside the sharp increase in EBITDA, Torrent Pharmaceuticals has also delivered an improvement in operating efficiency, as reflected in the EBITDA margin. The Q1 EBITDA margin stands at 33.81%, compared with 32.47% in the same quarter of the previous financial year. This margin expansion suggests better cost management, richer product mix, and possibly improved pricing power across key markets and segments. The combination of higher EBITDA and rising margins indicates that the company is not only growing in scale but also becoming more efficient and profitable on a per-rupee-of-revenue basis.
While revenue, PAT and street expectations are not specified in the available context, the strong year-on-year growth in EBITDA and the visible margin expansion point to a healthy operating trend for Torrent Pharmaceuticals in Q1. In the absence of additional data on net profit, revenue trajectory or market reaction, the focus remains on the clear improvement in operating performance. These developments are relevant for equity market participants tracking the pharmaceuticals sector on the NSE and BSE, as sustained margin improvement and EBITDA growth typically support medium-term valuations and can positively influence sentiment toward the stock.
Torrent Pharmaceuticals posts strong Q1 revenue growth on robust YoY performance
ResultTORNTPHARM30 Jul 2026
Torrent Pharmaceuticals has reported a sharp year-on-year increase in Q1 revenue, with topline rising to Rs 4,921.00 crores compared to Rs 3,178.00 crores in the corresponding quarter last year. This represents a strong expansion in scale for the company’s operations, indicating healthy demand across its key therapeutic segments and geographies. The revenue growth of roughly 55% YoY underscores a solid operational performance and suggests that the company has effectively leveraged its product portfolio, pricing, and market positioning during the quarter. Although detailed financial metrics such as EBITDA, PAT, and margin profiles are not provided in the available context, the reported numbers point to a materially higher business throughput versus the previous year.
In the absence of further breakdown on operating and net margins, cost structure, or one-off items, it is not possible to comment precisely on profitability trends or efficiency metrics. Similarly, no data is available on street expectations, consensus forecasts, or management guidance, so any assessment of outperformance versus analysts’ estimates or forward-looking commentary would be speculative and is therefore excluded. Market reaction, including intra-day or closing share price movement for TORNTPHARM on NSE/BSE following the result, is also not specified in the context and is not inferred. Based solely on the verifiable revenue figures, the Q1 performance signals a materially higher scale of operations compared with the prior year period, which is typically viewed as operationally positive for a listed pharmaceutical company, subject to confirmation from full result disclosures and margin/PAT details as they become available.
Torrent Pharmaceuticals posts modest year-on-year growth in Q1 consolidated profit
ResultTORNTPHARM30 Jul 2026
Torrent Pharmaceuticals has reported a year-on-year improvement in its consolidated profitability for the latest Q1 period, with consolidated net profit rising to Rs 566.00 crores from Rs 548.00 crores in the corresponding quarter last year. This represents a moderate increase in profit on an annual basis, indicating incremental earnings momentum for the company. The reported figures reflect performance at the consolidated level, capturing the overall profitability across Torrent Pharmaceuticals’ operations.
The available disclosure specifically highlights profit after tax, but does not provide accompanying details on revenue, EBITDA, or margin metrics for this quarter. As a result, trends in operating performance, such as operating margin or net margin changes, cannot be fully assessed from this context alone. Similarly, there is no information on quarter-on-quarter comparisons or management commentary, and no reference to how these results compare to street consensus or brokerage expectations. In the absence of verifiable data on revenue trajectory, cost dynamics, or segmental performance, the focus remains on the confirmed uptick in consolidated net profit on a year-on-year basis.
No immediate data is available in this context on the share price reaction of Torrent Pharmaceuticals on NSE or BSE following the result announcement, and there is no reference to broader sector or index-level impact. Given the nature of the information, the news represents a company-specific earnings update with limited macro or cross-market implications. The key takeaway is that Torrent Pharmaceuticals has delivered higher consolidated net profit compared to the same quarter last year, signaling stable to improving earnings, though further financial details would be required to draw deeper conclusions about operating performance, margins, and future guidance.
Torrent Pharmaceuticals appoints Shanti Ekambaram as additional independent director
Stock NewsTORNTPHARM28 Jul 2026
Torrent Pharmaceuticals has announced the appointment of Shanti Ekambaram as an additional independent director on its board, signalling a strengthening of its corporate governance and strategic oversight framework. Ekambaram is an experienced financial services professional and currently serves on the boards of Kotak Mahindra Bank, Kotak Mahindra Capital, Kotak Securities and Havells India, bringing extensive expertise in banking, capital markets, securities brokerage and consumer electricals. Her multi-sector board experience is likely to enhance the company’s ability to navigate regulatory complexity, capital allocation decisions and risk management in a dynamically changing healthcare and financial environment.
The appointment represents a management and board-level change rather than a capital structure event, with no accompanying disclosure in the provided context of equity dilution, fund-raising, buyback, dividend change or large-scale merger and acquisition activity. However, the addition of a seasoned independent director with deep banking and capital markets background could prove beneficial for Torrent Pharmaceuticals in areas such as funding strategy for future capex, potential inorganic opportunities, and optimisation of balance sheet leverage, particularly as the Indian pharmaceutical sector continues to grow and adapt to evolving domestic and global regulations. From an earnings and market share perspective, the near-term financial impact is expected to be indirect, driven mainly through improved strategic decision-making and governance, rather than immediate changes to revenue or profitability. The development is best classified as a routine but positive corporate governance update, with market impact likely limited to investor perception of board quality and long-term strategic stewardship in the healthcare and pharmaceuticals space.
Torrent Pharma recalls select Semalix pens, clarifies limited product impact
Stock NewsTORNTPHARM9 Jul 2026
Torrent Pharmaceuticals has initiated a targeted recall of certain batches of its Semalix semaglutide injection pens, while explicitly assuring that patient safety remains unaffected and that other semaglutide products in its portfolio are not impacted. Semalix is one of Torrent Pharma's key injectable semaglutide brands in India, positioned for the treatment of type 2 diabetes and obesity following the recent patent expiry that opened the market to multiple generic GLP-1 entrants. The current action appears limited to specific Semalix injection pens rather than a class-wide or molecule-wide issue, which materially restricts operational and reputational fallout versus a broader recall that might have affected all semaglutide offerings.
From an earnings and market-share perspective, the recall of selected Semalix pens could temporarily constrain sales volumes in affected SKUs and require additional logistics, quality assurance and replacement costs. However, Torrent Pharma's emphasis that patient safety is not compromised and that other semaglutide brands, such as its oral formulation and non-impacted injectable variants, continue unchanged, helps contain potential prescriber and patient concern. The company is likely to prioritize swift corrective actions, communication with healthcare professionals, and maintenance of supply for unaffected semaglutide products to defend its position in the fast-growing GLP-1 segment and protect longer-term revenue potential.
For equity investors, the development is operationally negative but appears manageable given its limited scope and the absence, so far, of reported adverse patient outcomes in the context provided. While there may be near-term sentiment pressure on the stock and some incremental compliance and quality-control expenditure, the lack of impact on other semaglutide products and the rapid corporate response reduce the probability of a structurally large earnings downgrade or sustained market-share erosion solely from this event. Overall, the recall represents a quality-control setback within a newly scaled product line rather than a broad-based regulatory or safety crisis for Torrent Pharma's semaglutide franchise.
Torrent Pharmaceuticals sees Rs 26.87 crores NSE block deal at set premium price
Block DealTORNTPHARM16 Jun 2026
Torrent Pharmaceuticals Ltd. witnessed a notable block trade on the NSE involving approximately 60,044 shares executed at a price of Rs 4,475.00 per share. The total deal size amounts to about Rs 26.87 crores, indicating meaningful institutional or large-investor activity in the counter. The transaction was executed as a block deal, typically conducted between large market participants through a single trade, outside the regular order-matching mechanism, to minimise market impact and price volatility during execution. However, the specific identities of the buyer and seller have not been disclosed in the available information, and there is no explicit clarity on whether the trade involved promoters, long-only institutional investors, domestic mutual funds, FIIs, or alternative investment funds.
The block size, at a little over sixty thousand shares, represents a relatively small fraction of Torrent Pharmaceuticals’ overall equity base, suggesting that the percentage stake change for either party is likely marginal in terms of total share capital. Given the absence of disclosed counterparties and lack of additional context such as whether this forms part of a broader strategic stake build-up, promoter stake rebalancing, or a pure secondary-market portfolio reallocation, the broader strategic implications remain limited from the information at hand. The block price of Rs 4,475.00 per share serves as an immediate reference level for near-term trading sentiment, although no explicit data is provided regarding the premium or discount versus the prevailing market price at the time of the transaction. There is also no verifiable detail available on the immediate follow-through price action in Torrent Pharmaceuticals’ stock post the deal, or on any associated movement in derivatives or volumes beyond the block window. As a result, the market read-through from this single transaction is primarily that of routine large-ticket secondary-market activity rather than a clearly directional corporate or macro signal.
Torrent Pharma jumps despite consolidated net profit falls 22% in Q4
Stock NewsTORNTPHARM25 May 2026
The total consolidated income of the company has increased by 42.13% at Rs 4,180.00 crore for Q4FY26

